Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/cid/ciaa1466 http://scihub22266oqcxt.onion/10.1093/cid/ciaa1466 33031500!7797739!33031500     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Infect+Dis 2021 ; 73 (11): e3996-e4004 Nephropedia Template TP {{tp|p=33031500|t=2021. Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019 |pdf=|usr=}}{{33031500}} gab.com Text Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019 JO: Clin Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33031500 #FOAvip BACKGROUND: Remdesivir is efficacious for severe coronavirus disease 2019 (COVID-19) in adults, but data in pregnant women are limited. We describe outcomes in the first 86 pregnant women with severe COVID-19 who were treated with remdesivir. METHODS: The reported data span 21 March to 16 June 2020 for hospitalized pregnant women with polymerase chain reaction-confirmed severe acute respiratory syndrome coronavirus 2 infection and room air oxygen saturation </=94% whose clinicians requested remdesivir through the compassionate use program. The intended remdesivir treatment course was 10 days (200 mg on day 1, followed by 100 mg for days 2-10, given intravenously). RESULTS: Nineteen of 86 women delivered before their first dose and were reclassified as immediate "postpartum" (median postpartum day 1 [range, 0-3]). At baseline, 40% of pregnant women (median gestational age, 28 weeks) required invasive ventilation, in contrast to 95% of postpartum women (median gestational age at delivery 30 weeks). By day 28 of follow-up, the level of oxygen requirement decreased in 96% and 89% of pregnant and postpartum women, respectively. Among pregnant women, 93% of those on mechanical ventilation were extubated, 93% recovered, and 90% were discharged. Among postpartum women, 89% were extubated, 89% recovered, and 84% were discharged. Remdesivir was well tolerated, with a low incidence of serious adverse events (AEs) (16%). Most AEs were related to pregnancy and underlying disease; most laboratory abnormalities were grade 1 or 2. There was 1 maternal death attributed to underlying disease and no neonatal deaths. CONCLUSIONS: Among 86 pregnant and postpartum women with severe COVID-19 who received compassionate-use remdesivir, recovery rates were high, with a low rate of serious AEs. Twit Text FOAVip Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019 ????Clin Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33031500 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33031500 #FOAvip English Wikipedia <ref>{{Cite pmid|33031500}}</ref> Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019 #MMPMID33031500 Burwick RM; Yawetz S; Stephenson KE; Collier AY; Sen P; Blackburn BG; Kojic EM; Hirshberg A; Suarez JF; Sobieszczyk ME; Marks KM; Mazur S; Big C; Manuel O; Morlin G; Rose SJ; Naqvi M; Goldfarb IT; DeZure A; Telep L; Tan SK; Zhao Y; Hahambis T; Hindman J; Chokkalingam AP; Carter C; Das M; Osinusi AO; Brainard DM; Varughese TA; Kovalenko O; Sims MD; Desai S; Swamy G; Sheffield JS; Zash R; Short WR Clin Infect Dis 2021[Dec]; 73 (11): e3996-e4004 PMID33031500show ga BACKGROUND: Remdesivir is efficacious for severe coronavirus disease 2019 (COVID-19) in adults, but data in pregnant women are limited. We describe outcomes in the first 86 pregnant women with severe COVID-19 who were treated with remdesivir. METHODS: The reported data span 21 March to 16 June 2020 for hospitalized pregnant women with polymerase chain reaction-confirmed severe acute respiratory syndrome coronavirus 2 infection and room air oxygen saturation |*COVID-19 Drug Treatment[MESH] |*Pregnancy Complications, Infectious/drug therapy[MESH] |Adenosine Monophosphate/analogs & derivatives[MESH] |Adult[MESH] |Alanine/analogs & derivatives[MESH] |Compassionate Use Trials[MESH] |Female[MESH] |Humans[MESH] |Infant[MESH] |Oxygen Saturation[MESH] |Pregnancy[MESH] |Pregnant Women[MESH]Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavi(epmc).pdf DeepDyve Pubget Overpricing